<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>医药魔方Info | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2021-01-19T16:49:49+08:00</updated>
  <subtitle>传递医药信息，分享资源数据！充电5分钟，吹牛2小时！</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>小分子RNA靶向疗法热潮渐起，全球制药巨头纷涌而至</title>
    <updated>2021-01-19T16:07:50+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-19:/s/yBePyjnOCIetg692SqvDrg</id>
    <link href="https://mp.weixin.qq.com/s/yBePyjnOCIetg692SqvDrg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>博安生物新冠中和抗体完成 I 期临床全部受试者入组</title>
    <updated>2021-01-19T16:07:50+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-19:/s/a21EtUlaAfB8FByMElIOwg</id>
    <link href="https://mp.weixin.qq.com/s/a21EtUlaAfB8FByMElIOwg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>国内首个！博雅辑因CRISPR/Cas 9基因编辑疗法获批临床，治疗β地中海贫血</title>
    <updated>2021-01-19T16:07:50+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-19:/s/8jSJ1LFkeKInhsCqeLLs0w</id>
    <link href="https://mp.weixin.qq.com/s/8jSJ1LFkeKInhsCqeLLs0w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>辉瑞克唑替尼新适应症获FDA批准，治疗ALK阳性间变性大细胞淋巴瘤</title>
    <updated>2021-01-15T15:31:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/wVndKSCvikc2KMCD82caHg</id>
    <link href="https://mp.weixin.qq.com/s/wVndKSCvikc2KMCD82caHg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>诺华下一代IgE抗体 ligelizumab 获FDA突破性疗法认定</title>
    <updated>2021-01-15T15:31:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/jNDWOV2F9sARjhEpH7ehmA</id>
    <link href="https://mp.weixin.qq.com/s/jNDWOV2F9sARjhEpH7ehmA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>临床急需新药「布罗舒单抗」今日在华获批上市</title>
    <updated>2021-01-15T15:31:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/DPm8R_mbB-dwI9IBecq7og</id>
    <link href="https://mp.weixin.qq.com/s/DPm8R_mbB-dwI9IBecq7og" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>FDA授予默沙东15价肺炎球菌结合疫苗优先审评资格</title>
    <updated>2021-01-15T15:31:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/kSr7nj6P8jRnrLxZUlPZNQ</id>
    <link href="https://mp.weixin.qq.com/s/kSr7nj6P8jRnrLxZUlPZNQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>中国首个! 瑞欣妥®在华重磅获批 绿叶制药创新微球技术展现全球领先优势</title>
    <updated>2021-01-14T14:38:18+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/OguBUdW4kvsi42V9nKT30Q</id>
    <link href="https://mp.weixin.qq.com/s/OguBUdW4kvsi42V9nKT30Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>百济神州PD-1第3个适应症获批！一线治疗鳞状NSCLC</title>
    <updated>2021-01-14T14:38:18+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/xzFPNh5u1WxTcTI66LGvbQ</id>
    <link href="https://mp.weixin.qq.com/s/xzFPNh5u1WxTcTI66LGvbQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>复宏汉霖达雷妥尤单抗生物类似药获批临床，治疗多发性骨髓瘤</title>
    <updated>2021-01-14T14:38:18+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/Qlh0Mpx780Bi-N7F1W6Jpg</id>
    <link href="https://mp.weixin.qq.com/s/Qlh0Mpx780Bi-N7F1W6Jpg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>拜耳first-in-class疗法获FDA优先审评资格，治疗糖尿病肾病</title>
    <updated>2021-01-14T14:38:18+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/d1tMMh_7iY1cxpd8xzo1Rw</id>
    <link href="https://mp.weixin.qq.com/s/d1tMMh_7iY1cxpd8xzo1Rw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>JP摩根现场：今年的交易，中国企业比以往来得更猛一些……</title>
    <updated>2021-01-13T14:22:03+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-13:/s/yGTjFe9UEiAhzV7bxyLk3Q</id>
    <link href="https://mp.weixin.qq.com/s/yGTjFe9UEiAhzV7bxyLk3Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>领袖汇聚倒计时丨中国肿瘤医药营销趋势论坛—市场及销售分论坛</title>
    <updated>2021-01-13T14:22:03+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-13:/s/MJumnqImhpR1IotQcRraFw</id>
    <link href="https://mp.weixin.qq.com/s/MJumnqImhpR1IotQcRraFw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>信达生物提交信迪利单抗+贝伐珠单抗一线治疗肝癌上市申请</title>
    <updated>2021-01-13T14:22:03+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-13:/s/G7PXnNDp8wuBGHJs0nzWkA</id>
    <link href="https://mp.weixin.qq.com/s/G7PXnNDp8wuBGHJs0nzWkA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>罗氏“T+A”方案显著改善肝癌患者总生存期，中国亚群OS突破24个月</title>
    <updated>2021-01-13T14:22:03+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-13:/s/TEJadrL536YtdiDLS0NPpQ</id>
    <link href="https://mp.weixin.qq.com/s/TEJadrL536YtdiDLS0NPpQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>国内首个CAR-T疗法！复星凯特Yescarta即将获批上市</title>
    <updated>2021-01-12T13:27:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/SfmLjidgMynlgtUbe0Lsbw</id>
    <link href="https://mp.weixin.qq.com/s/SfmLjidgMynlgtUbe0Lsbw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>领袖汇聚倒计时丨中国肿瘤医药营销趋势论坛—准入及支付分论坛</title>
    <updated>2021-01-12T13:27:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/XuIS4-yK7--uVRF9OsucjA</id>
    <link href="https://mp.weixin.qq.com/s/XuIS4-yK7--uVRF9OsucjA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>CDE拟突破性疗法认定：安进KRAS抑制剂AMG 510治疗NSCLC</title>
    <updated>2021-01-12T13:27:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/LfPe0I6uNci5cONrCMrXcA</id>
    <link href="https://mp.weixin.qq.com/s/LfPe0I6uNci5cONrCMrXcA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>礼来阿尔茨海默病β淀粉样蛋白抗体疗法达到II期临床主要终点</title>
    <updated>2021-01-12T13:27:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/3jbqnX_Ym8UQ-a7CBcBw_g</id>
    <link href="https://mp.weixin.qq.com/s/3jbqnX_Ym8UQ-a7CBcBw_g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>信达生物提交信迪利单抗二线治疗鳞状NSCLC上市申请</title>
    <updated>2021-01-12T13:27:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/OwglasT25ZhRLjhMB-vRzg</id>
    <link href="https://mp.weixin.qq.com/s/OwglasT25ZhRLjhMB-vRzg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>